hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-04 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Banting was appointed Senior Demonstrator in Medicine at the University of Toronto in 1922. Next year he was elected to the new Banting and Best Chair of Medical Research, endowed by the Legislature of the province of Ontario. He also served as Honorary Consulting Physician to the Toronto General, the Hospital for Sick Children, and the Toronto Western Hospital. At the Banting and Best Institute, he focused his research on silicosis, cancer, and the mechanisms of drowning. In 1938, Banting's interest in aviation medicine resulted in his participation with the Royal Canadian Air Force (RCAF) in research concerning the physiological problems encountered by pilots operating high-altitude combat aircraft. Banting headed the RCAF's Number 1 Clinical Investigation Unit (CIU), which was housed in a secret facility on the grounds of the former Eglinton Hunt Club in Toronto. During the Second World War he investigated the problems of aviators, such as "blackout" (syncope). He also helped Wilbur Franks with the invention of the G-suit to stop pilots from blacking out when they were subjected to g-forces while turning or diving. Another of Banting's projects during the Second World War involved using and treating mustard gas burns. Banting even tested the gas and antidotes on himself to see if they were effective.
=== Organosilanes === Organosilanes create a network of electrically charged molecules on the surface, which rupture the cell wall on contact. This is due to their structure which consists of a hydrophobic element and a cationic element. While the hydrophobic element may prevent adherence in the first place, it may also intercalate with the cell wall, whose rupture is aided by the cationic component.
=== Adobe ColdFusion (2018 Release) === Adobe ColdFusion (2018 release), known generically as ColdFusion 2018, was released on July 12, 2018. ColdFusion 2018 was codenamed Aether during prerelease. As of March 2023, Adobe had released 16 updates for ColdFusion 2018. New or improved features available in all editions (Standard, Enterprise, and Developer) include:
Sources: en.wikipedia.org
military states that one of its soldiers was killed and another soldier was slightly wounded in north of Iraq the previous day, "during a controlled detonation of unexploded ordnance from a downed Iranian one-way attack drone." 2026 FIFA World Cup final: Spain beat defending champions Argentina 1–0 after extra time at the MetLife Stadium in East Rutherford, New Jersey to win a second FIFA World Cup title. July 20 – 2026 Iran war: The U.S. military conducts a ninth consecutive night of strikes on Iranian targets, which President Trump says are retaliation for the deaths of three American soldiers. July 21 The US announces a trade agreement with Jordan. The US begins allowing direct flights between the US and Lebanon for the first time since 1985. OpenAI reveals that an autonomous artificial intelligence agent powered by its models escaped a controlled testing environment and compromised the computer systems of Hugging Face while attempting to obtain answers to a cybersecurity evaluation. OpenAI describes it as an "unprecedented cyber incident". July 22 2026 Iran war: The US conducts its 11th consecutive night of strikes in Iran. Trump states that the US would strike and destroy Iran's bridges and power plants for each ship it attacks in the Strait of Hormuz. The U.S. signs a deal with Saudi Arabia to develop a civilian nuclear program in the country. Trump demands that Saudi Arabia join the Abraham Accords so that the agreement will take effect. July 23 2026 Iran war: The US conducts its 12th consecutive night of strikes in Iran.
Non-specific active immunotherapy: generating a general immune system response using cytokines and other cell signaling molecules. Specific active immunotherapy: the generation of cell-mediated and antibody immune responses focused on specific antigens expressed by the cancer cells, typically using a vaccine platform. Active immunotherapies fall under the category of activation immunotherapies, which is a subset of immunotherapies that activate the immune system as opposed immunotherapies that suppress the immune system. Non-specific active immunotherapy is administered with the overall goal of generally eliminating malignant pathogens or cells from the host system. This treatment stimulates the immune system in a general sense, rather than specifically targeting a cell type e.g. cancer cells. Non-specific approaches aim to create a robust immune response that would lead to the eventual killing of malignant cells through immunomodulators such as cytokines.
== Use outside archaeology == Archaeology is not the only field that uses radiocarbon dating. Radiocarbon dates can also be used in geology, sedimentology, and lake studies, for example. The ability to date minute samples using AMS has meant that palaeobotanists and palaeoclimatologists can use radiocarbon dating directly on pollen purified from sediment sequences, or on small quantities of plant material or charcoal. Dates on organic material recovered from strata of interest can be used to correlate strata in different locations that appear to be similar on geological grounds. Dating material from one location gives date information about the other location, and the dates are also used to place strata in the overall geological timeline. Radiocarbon is also used to date carbon released from ecosystems, particularly to monitor the release of old carbon that was previously stored in soils as a result of human disturbance or climate change. Recent advances in field collection techniques also allow the radiocarbon dating of methane and carbon dioxide, which are important greenhouse gases.
==== Direct recycling ==== Direct recycling is the removal of the cathode or anode from the electrode, which are then reconditioned and reused in a new battery. Mixed metal-oxides can be added to the new electrode with very little change to the crystal morphology. The process generally involves the addition of new lithium to replenish the loss of lithium in the cathode due to degradation from cycling. Cathode strips are obtained from the dismantled batteries, then soaked in NMP, and undergo sonication to remove excess deposits. It is treated hydrothermally with a solution containing LiOH/Li2SO4 before annealing. This method is extremely cost-effective for noncobalt-based batteries as the raw materials do not make up the bulk of the cost. Direct recycling avoids the time-consuming and expensive purification steps, which is great for low-cost cathodes such as LiMn2O4 and LiFePO4. For these cheaper cathodes, most of the cost, embedded energy, and carbon footprint is associated with the manufacturing rather than the raw material. It is experimentally shown that direct recycling can reproduce similar properties to pristine graphite. The drawback of the method lies in the condition of the retired battery. In the case where the battery is relatively healthy, direct recycling can cheaply restore its properties. However, for batteries where the state of charge is low, direct recycling may not be worth the investment. The process must also be tailored to the specific cathode composition, and therefore the process must be configured to one type of battery at a time.
Sources: en.wikipedia.org
People who have been fat since childhood generally have an inflated number of fat cells. People who become fat as adults may have no more fat cells than their lean peers, but their fat cells are larger. In general, people with an excess of fat cells find it harder to lose weight and keep it off than the obese who simply have enlarged fat cells.
Liquid–liquid extraction (also called 'solvent extraction' or 'partitioning') is a common method for extracting a substance from one liquid into another liquid at a different 'phase' (such as "slurry"). This method, which implements a countercurrent mechanism, is used in nuclear reprocessing, ore processing, the production of fine organic compounds, the processing of perfumes, the production of vegetable oils and biodiesel, and other industries. Gold can be separated from a cyanide solution with the Merrill–Crowe process using Counter Current Decantation (CCD). In some mines, nickel and cobalt are treated with CCD, after the original ore was treated with concentrated sulfuric acid and steam in titanium covered autoclaves, producing nickel cobalt slurry. The nickel and cobalt in the slurry are removed from it almost completely using a CCD system exchanging the cobalt and nickel with flash steam heated water.
Mindlin (1928), engineer, Medal for Merit and ASME Medal recipient Harold Charles Bold (1929), botanist Jule Eisenbud (1929), psychiatrist known for research into parapsychology Theodore Lidz (1930), Sterling Professor of psychiatry at Yale; expert on schizophrenia Judd Marmor (1930), psychoanalyst and psychiatrist on homosexuality Herbert L. Anderson (1931), director of the Enrico Fermi Institute, professor of the University of Chicago Paul E. Queneau (1931), professor of metallurgical engineering at Dartmouth College Bernard Glueck Jr. (1933), psychiatrist, former president of the American Psychopathological Association Irving Kaplan (1933), chemist, professor at Massachusetts Institute of Technology Leo Rangell (1933), psychoanalyst; president of the International Psychoanalytical Association and the American Psychoanalytic Association John K. Lattimer (1935), urologist, ballistics expert, and inveterate collector Emanuel Papper (1935), anesthesiologist, dean of the Miller School of Medicine at the University of Miami 1969–1981 Norman Foster Ramsey Jr. (1935), winner of the Nobel Prize in Physics Robert Marshak (1936), president of the American Physical Society and president of the City College of New York Julian Schwinger (1936), winner of the Nobel Prize in Physics; posited the Schwinger effect Barry Commoner (1937), leading environmentalist, former editor of Science Illustrated magazine Francis J. Ryan (1937), professor of zoology at Columbia University Boris Jacobsohn (1938), professor of Physics at the University of Washington David B.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.